Douglas S. Ingram
Chief Executive Officer
Chase Pharmaceuticals Corporation
United States of America
Douglas S. Ingram, Chief Executive Officer, brings 20 years of biotech, pharmaceutical and medical device leadership to Chase. Most recently and until its acquisition by Actavis in early 2015, he was President of Allergan, a global pharmaceutical company with franchises in Neuroscience, Urology, Ophthalmology and Medical Aesthetics. Previously, Mr. Ingram was President of Allergan’s operations in Europe, the Middle East, and Africa. Earlier at Allergan he was responsible for building and leading numerous aspects of the global organization including Legal Affairs, Regulatory Affairs and Pharmacovigilance, Information Technology, Public Relations and External Communication, Human Resources, and Audit and Compliance. In addition to Chase Pharmaceuticals, Mr. Ingram is a board member of Endo International plc, Pacific Life Insurance Company and Nemus Biosciences. He is also the co-founder and limited liability partner of the OC Marathon. Mr. Ingram received his Bachelor of Science Degree, Magna Cum Laude, from Arizona State University, in 1985 and his Juris Doctorate, Summa Cum Laude and Order of the Coif, from the James E. Rogers College of Law, University of Arizona in 1988.
Chase Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders, including Alzheimer’s disease. The company’s development programs have the potential to profoundly improve the symptomatic treatment of Alzheimer's disease.